| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | PFE | Common Stock | Options Exercise | $204,202 | +8,921 | +42% | $22.89 | 30,127 | 25 Feb 2023 | Direct | F1 |
| transaction | PFE | Common Stock | Tax liability | $74,566 | -1,786 | -5.9% | $41.75 | 28,341 | 25 Feb 2023 | Direct | F2, F3 |
| transaction | PFE | Common Stock | Tax liability | $172,326 | -3,967 | -14% | $43.44 | 24,374 | 25 Feb 2023 | Direct | F4, F5 |
| transaction | PFE | Common Stock | Tax liability | $52,892 | -1,297 | -5.3% | $40.78 | 23,077 | 27 Feb 2023 | Direct | F6 |
| holding | PFE | Common Stock | 10,375 | 25 Feb 2023 | By Rule 16b-3 Plan |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | PFE | Stock Appreciation Rights | Options Exercise | $0 | -8,921 | -100% | $0.000000* | 0 | 25 Feb 2023 | Common Stock | 8,921 | $22.89 | Direct |
| Id | Content |
|---|---|
| F1 | The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). |
| F2 | The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. |
| F3 | Price is the closing price of Pfizer common stock on February 24, 2023. |
| F4 | The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). |
| F5 | Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. |
| F6 | The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon). |